



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission	6	Attorney Docket No.	200130.494/1581.002
--	---	---------------------	---------------------

Application Number	09/678,159
Filing Date	October 2, 2000
First Named Inventor	Keting Chu
Group Art Unit	Not Assigned
Examiner Name	Not Assigned


1617
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
MARCH 22, 2001
TRANSMITTAL FORM

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> General Authorization under 37 C.F.R. § 1.36(a)(3) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <u>Forms PTO-1449 (3 Sheets)</u> <u>Return Receipt Postcard</u> <u>Cited References (25)</u>
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund <input type="checkbox"/> CD(s), Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name/ Firm Name	Jane E.R. Potter Seed Intellectual Property Law Group PLLC 701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092 Phone: (206) 622-4900 Fax: (206) 682-6031	 00500 <small>PATENT TRADEMARK OFFICE</small>
Signature		
Date	3/14/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Nathan Adderson	
Signature		Date: 3/15/01



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Keting Chu and Changyu Wang
Application No. : 09/678,159
Filed : October 2, 2000
For : COMPOSITIONS AND METHODS FOR TREATING PSORIASIS

Docket No. : 200130.494/1581.002

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.


Applicants wish to disclose and have officially considered the following copending applications by the same assignee:

Application No.	Title	Filed
60/237,556	Generation of Human Anti-Human CD40 Antibodies to Block CD40-CD40L Interaction	October 2, 2000

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E.R. Potter
Registration No. 33,332

JEP:nka

Enclosures:

- Postcard
- Form PTO/SB/21
- Form PTO-1449 (3 sheets)
- Cited References (25)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

L:\200130 - Chiron\494\Ids\DSCL.doc